` 1PK (Dechra Pharmaceuticals PLC) vs DAX Index Comparison - Alpha Spread

D
1PK
vs
D
DAX Index

Over the past 12 months, 1PK has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +13% growth.

Stocks Performance
1PK vs DAX Index

Loading
1PK
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
1PK vs DAX Index

Loading
1PK
DAX Index
Difference
www.alphaspread.com

Performance By Year
1PK vs DAX Index

Loading
1PK
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Dechra Pharmaceuticals PLC vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Dechra Pharmaceuticals PLC
Glance View

Market Cap
5.1B EUR
Industry
Pharmaceuticals

Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.

1PK Intrinsic Value
Not Available
D
Back to Top